Literature DB >> 27839907

Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

Hubert Kolb1, Matthias von Herrath2.   

Abstract

T cell-directed immunosuppression only transiently delays the loss of β cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and β cell proliferation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2016        PMID： 27839907     DOI： 10.1016/j.cmet.2016.10.009

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  15 in total

1.  Gut microbiota metabolites for sweetening type I diabetes.

Authors:  Thamer Aljutaily; Marta Consuegra-Fernández; Fernando Aranda; Francisco Lozano; Eduardo Huarte
Journal:  Cell Mol Immunol       Date:  2017-07-31       Impact factor: 11.530

Review 2.  Antibiotics, gut microbiota, environment in early life and type 1 diabetes.

Authors:  Youjia Hu; F Susan Wong; Li Wen
Journal:  Pharmacol Res       Date:  2017-02-07       Impact factor: 7.658

3.  B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Authors:  Peter S Linsley; Carla J Greenbaum; Cate Speake; S Alice Long; Matthew J Dufort
Journal:  JCI Insight       Date:  2019-02-21

Review 4.  Interactions between islets and regulatory immune cells in health and type 1 diabetes.

Authors:  Matthew A Budd; Mahdis Monajemi; Sarah J Colpitts; Sarah Q Crome; C Bruce Verchere; Megan K Levings
Journal:  Diabetologia       Date:  2021-09-22       Impact factor: 10.122

5.  Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes".

Authors:  Carolin Daniel; Benno Weigmann; Harald von Boehmer
Journal:  J Exp Med       Date:  2017-05-23       Impact factor: 14.307

Review 6.  Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes.

Authors:  Arata Itoh; William M Ridgway
Journal:  Immunotargets Ther       Date:  2017-05-19

7.  A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

Authors:  Laurence B Peterson; Charles J M Bell; Sarah K Howlett; Marcin L Pekalski; Kevin Brady; Heather Hinton; Denise Sauter; John A Todd; Pablo Umana; Oliver Ast; Inja Waldhauer; Anne Freimoser-Grundschober; Ekkehard Moessner; Christian Klein; Ralf J Hosse; Linda S Wicker
Journal:  J Autoimmun       Date:  2018-11-13       Impact factor: 7.094

8.  Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.

Authors:  Danielle M Gerlag; Mary Safy; Karen I Maijer; Man Wai Tang; Sander W Tas; Mirian J F Starmans-Kool; Astrid van Tubergen; Matthijs Janssen; Maria de Hair; Monika Hansson; Niek de Vries; Aeilko H Zwinderman; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2018-12-01       Impact factor: 19.103

9.  The Autoantigenic Proinsulin B-Chain Peptide B11-23 Synergises with the 70 kDa Heat Shock Protein DnaK in Macrophage Stimulation.

Authors:  Elias Blasius; Elke Gülden; Hubert Kolb; Christiane Habich; Volker Burkart
Journal:  J Diabetes Res       Date:  2018-12-09       Impact factor: 4.011

10.  Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.

Authors:  Maigan A Brusko; Joshua M Stewart; Amanda L Posgai; Clive H Wasserfall; Mark A Atkinson; Todd M Brusko; Benjamin G Keselowsky
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.